With the advent of the genetic era in Parkinson's disease (PD) research in 1997, α-synuclein
was identified as an important player in a complex neurodegenerative disease that affects> …

The development of atomic force microscopy (AFM) has opened up a wide range of novel
opportunities in nanoscience and new modalities of observation in complex biological …

Protein aggregation is a complex process resulting in the formation of heterogeneous
mixtures of aggregate populations that are closely linked to neurodegenerative conditions …

The spontaneous assembly of proteins into amyloid fibrils is a phenomenon central to many
increasingly common and currently incurable human disorders, including Alzheimer's and …

Nanobodies are antibody fragments derived from camelids, naturally endowed with
properties like low molecular weight, high affinity and low immunogenicity, which contribute …

Misfolding and aggregation of the proteins amyloid‐β, tau and alpha‐synuclein is the
predominant pathology underlying the neurodegenerative disorders, Alzheimer's and …

Amyloid fibrils are β-sheet-rich linear protein polymers that can be formed by a large variety
of different proteins. These assemblies have received much interest in recent decades, due …

α-Synuclein (asyn) is a key pathogenetic factor in a group of neurodegenerative diseases
generically known as synucleinopathies, including Parkinson's disease (PD), dementia with …

Therapeutics designed to target α-synuclein (α-syn) aggregation may be critical in halting
the progression of pathology in Parkinson's disease (PD) patients. Nanobodies are single …

HER2-targeted therapies have drastically improved the outcome for breast cancer patients.
However, when metastasis to the brain is involved, current strategies fail to hold up to the …